[go: up one dir, main page]

DK3091029T5 - Anti-IL13-antistofformuleringer - Google Patents

Anti-IL13-antistofformuleringer Download PDF

Info

Publication number
DK3091029T5
DK3091029T5 DK16169916.0T DK16169916T DK3091029T5 DK 3091029 T5 DK3091029 T5 DK 3091029T5 DK 16169916 T DK16169916 T DK 16169916T DK 3091029 T5 DK3091029 T5 DK 3091029T5
Authority
DK
Denmark
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
DK16169916.0T
Other languages
English (en)
Other versions
DK3091029T3 (da
Inventor
Ajay Deshmukh
Joumana Zeid
Thomas M Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3091029T3 publication Critical patent/DK3091029T3/da
Publication of DK3091029T5 publication Critical patent/DK3091029T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
DK16169916.0T 2011-10-31 2012-10-30 Anti-IL13-antistofformuleringer DK3091029T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553916P 2011-10-31 2011-10-31
EP12846324.7A EP2773662A4 (en) 2011-10-31 2012-10-30 ANTIBODY FORMULATIONS

Publications (2)

Publication Number Publication Date
DK3091029T3 DK3091029T3 (da) 2023-01-30
DK3091029T5 true DK3091029T5 (da) 2024-10-14

Family

ID=48192677

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16169916.0T DK3091029T5 (da) 2011-10-31 2012-10-30 Anti-IL13-antistofformuleringer

Country Status (27)

Country Link
US (3) US10000562B2 (da)
EP (3) EP3091029B1 (da)
JP (4) JP6120452B2 (da)
KR (4) KR101994809B1 (da)
CN (4) CN104039826A (da)
AR (2) AR088579A1 (da)
AU (3) AU2012332767C1 (da)
BR (1) BR112014008864B1 (da)
CA (2) CA2849210C (da)
DK (1) DK3091029T5 (da)
ES (1) ES2936387T3 (da)
FI (1) FI3091029T3 (da)
HK (1) HK1201857A1 (da)
HR (1) HRP20230153T1 (da)
HU (1) HUE061728T2 (da)
IL (2) IL232053B (da)
LT (1) LT3091029T (da)
MX (2) MX363226B (da)
MY (2) MY187874A (da)
PL (1) PL3091029T3 (da)
PT (1) PT3091029T (da)
RS (1) RS63948B1 (da)
RU (1) RU2665810C2 (da)
SG (1) SG11201401903PA (da)
SI (1) SI3091029T1 (da)
WO (1) WO2013066866A1 (da)
ZA (2) ZA201401779B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2013066426A2 (en) 2011-06-24 2013-05-10 Kci Licensing, Inc. Reduced-pressure dressings employing tissue-fixation elements
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DK2771031T3 (da) 2011-10-28 2018-05-28 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
RS63948B1 (sr) 2011-10-31 2023-02-28 Hoffmann La Roche Formulacije anti-il13 antitela
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CN104619724B (zh) 2012-01-27 2018-05-04 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
MY176026A (en) * 2013-09-13 2020-07-22 Genentech Inc Methods and composions comprising purified recombinant polypeptides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
JPWO2015079977A1 (ja) * 2013-11-26 2017-03-16 シャープ株式会社 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2016102068A1 (en) 2014-12-23 2016-06-30 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
BR112018072263A2 (pt) 2016-04-27 2019-02-12 Abbvie Inc. métodos de tratamento de doenças nas quais atividade de il-13 é prejudicial usando anti-anticorpos anti-il-13
SI3528838T1 (sl) * 2016-09-23 2023-10-30 F. Hoffmann-La Roche Ag Uporabe IL-13 antagonistov za zdravljenje atopijskega dermatitisa
AU2018207367B2 (en) * 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
WO2020142096A1 (en) * 2019-01-02 2020-07-09 M & J Scientific, Llc Light scattering detectors and methods for the same
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
JP2023502777A (ja) * 2019-11-26 2023-01-25 コメラ ライフ サイエンシズ，インコーポレイテッド バイオポリマー製剤のための賦形剤化合物
US20230406920A1 (en) * 2020-10-22 2023-12-21 Allakos Inc. Anti-siglec-8 antibody formulations
TWI847170B (zh) 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
EP4402169A1 (en) 2021-09-15 2024-07-24 Dermira, Inc. Il-13 inhibitors for the treatment of prurigo nodularis
EP4519315A1 (en) 2022-05-05 2025-03-12 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis
WO2024186796A1 (en) 2023-03-08 2024-09-12 Dermira, Inc. Il-13 antibodies for the treatment of atopic dermatitis

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP0779806B2 (en) 1994-09-09 2008-04-16 Takeda Pharmaceutical Company Limited Sustained release preparation containing metal salt of a peptide
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
HUP9900870A3 (en) 1995-06-07 2001-04-28 Alkermes Inc Composition for sustained release of human growth hormone
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
RU2319503C2 (ru) * 2001-11-07 2008-03-20 Цитос Байотекнолоджи Аг Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EA009079B1 (ru) * 2003-02-28 2007-10-26 Арес Трейдинг С.А. Жидкие составы фактор некроза опухоли-связывающих белков
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
HRP20231569T1 (hr) * 2003-12-23 2024-03-15 Genentech, Inc. Nova protutijela protiv il 13 i njihova upotreba
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1942939B2 (en) 2005-09-30 2021-07-07 Medimmune Limited Interleukin-13 antibody composition
PT2532679T (pt) * 2005-10-21 2017-07-18 Novartis Ag Anticorpos humanos contra il13 e utilizações terapêuticas
WO2007076062A2 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CN101600457B (zh) * 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CA2745525A1 (en) * 2008-12-03 2010-06-10 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
KR20110128333A (ko) * 2009-03-06 2011-11-29 제넨테크, 인크. 항체 제제
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
MX354867B (es) * 2010-03-22 2018-03-23 Genentech Inc Star Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
RS63948B1 (sr) 2011-10-31 2023-02-28 Hoffmann La Roche Formulacije anti-il13 antitela

Also Published As

Publication number Publication date
HRP20230153T1 (hr) 2023-03-31
EP4218937A2 (en) 2023-08-02
HK1201857A1 (en) 2015-09-11
PL3091029T3 (pl) 2023-04-11
KR101994809B1 (ko) 2019-07-01
JP6120452B2 (ja) 2017-04-26
FI3091029T3 (fi) 2023-03-20
CN109078182B (zh) 2022-08-12
EP3091029B1 (en) 2022-12-28
MY187874A (en) 2021-10-26
IL276234B (en) 2022-04-01
ZA201401779B (en) 2019-07-31
AU2012332767B2 (en) 2016-05-12
CA3078979C (en) 2022-10-11
JP6921148B2 (ja) 2021-08-18
KR20140084078A (ko) 2014-07-04
SG11201401903PA (en) 2014-05-29
MX363226B (es) 2019-03-15
MX2019002979A (es) 2020-02-10
AR124140A2 (es) 2023-02-15
LT3091029T (lt) 2023-02-27
US10000562B2 (en) 2018-06-19
EP2773662A1 (en) 2014-09-10
KR20200065104A (ko) 2020-06-08
CN108704132A (zh) 2018-10-26
AU2018232943B2 (en) 2020-07-23
AU2012332767A1 (en) 2014-04-10
CA2849210C (en) 2020-07-14
ZA201901490B (en) 2021-06-30
RS63948B1 (sr) 2023-02-28
KR20170096212A (ko) 2017-08-23
IL276234A (en) 2020-09-30
JP2018048166A (ja) 2018-03-29
EP2773662A4 (en) 2015-07-01
NZ622654A (en) 2017-01-27
KR102259829B1 (ko) 2021-06-03
PT3091029T (pt) 2023-02-03
WO2013066866A1 (en) 2013-05-10
JP2016193922A (ja) 2016-11-17
CN116077644A (zh) 2023-05-09
US10947307B2 (en) 2021-03-16
BR112014008864A2 (pt) 2018-08-07
CN104039826A (zh) 2014-09-10
KR20190077127A (ko) 2019-07-02
MX2014004992A (es) 2014-08-27
US20210155684A1 (en) 2021-05-27
RU2014116070A (ru) 2015-12-10
AU2018232943A1 (en) 2018-10-11
CA3078979A1 (en) 2013-05-10
US20140348855A1 (en) 2014-11-27
EP4218937A3 (en) 2023-10-25
RU2665810C2 (ru) 2018-09-04
JP6272950B2 (ja) 2018-01-31
AU2012332767C1 (en) 2017-02-02
IL232053B (en) 2020-08-31
HUE061728T2 (hu) 2023-08-28
SI3091029T1 (sl) 2023-03-31
BR112014008864B1 (pt) 2021-11-09
MY197851A (en) 2023-07-20
JP2019203002A (ja) 2019-11-28
JP2014532664A (ja) 2014-12-08
DK3091029T3 (da) 2023-01-30
IL232053A0 (en) 2014-05-28
EP3091029A1 (en) 2016-11-09
AU2016210757A1 (en) 2016-08-25
AR088579A1 (es) 2014-06-18
CN109078182A (zh) 2018-12-25
ES2936387T3 (es) 2023-03-16
CA2849210A1 (en) 2013-05-10
US20190002552A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
DK3091029T5 (da) Anti-IL13-antistofformuleringer
DK3117837T3 (da) Antistofformuleringer
SI3725778T1 (sl) Formulacije enzalutamida
DK3620175T3 (da) Højkoncentrerede antistofformuleringer
PT2720563T (pt) Resumo
EP2782540A4 (en) CHAIR WITH ROLLERS
DK2694038T3 (da) Farmaceutisk sammensætning
DK3275892T3 (da) Præfusions-rsv-f-antigener
BR112013022112A2 (pt) composição
BR112014002399A2 (pt) conjunto
EP2673344A4 (en) STABLE BIO OIL
CO6801637A2 (es) Formulaciones de anticuerpos
BR112013022102A2 (pt) composição
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
CO6940426A2 (es) Formulaciones farmacéuticas
CO6761402A2 (es) Formulaciones inmunosupresoras
BR112014000015A2 (pt) formulação
BR112013033808A2 (pt) composição
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
BR112014005756A2 (pt) vacina
PT2661870T (pt) Resumo
HRP20181667T1 (hr) Pripravak
EP2769718A4 (en) MEDICAL COMPOSITION
IL231660A0 (en) Composition